Germany Diabetes Market

Market Overview:

The Germany diabetes market size reached US$ 11.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.8 Billion by 2032, exhibiting a growth rate (CAGR) of 2.9% during 2024-2032.

According to the International Diabetes Federation, diabetes is one of the most prevalent chronic diseases in Germany, with 9.5 million recorded incidences in 2019. Diabetes is a set of diseases caused by issues with insulin – a hormone produced by the pancreas that regulates blood sugar. During these conditions, either the pancreas does not produce the required amount of insulin or the body is not able to effectively use the hormone. There are three major types of diabetes, which include type 1, type 2 and gestational diabetes. Amongst these, type 1 diabetes is an autoimmune condition, which occurs when the body starts attacking the pancreas with antibodies that disable the organ to make insulin. Whereas, type 2 diabetes is a milder form of type 1 diabetes, where the insulin created by the pancreas is either not enough for the body or the latter is resistant to it. Gestational diabetes generally develops during the second or third trimester of pregnancy and disappears after delivery.

Despite several improvements and advancements in its detection and treatment processes, diabetes remains one of the primary reasons for severe complications in most patients in Germany, which include heart attacks, strokes, end-stage renal disease, blindness, and amputations of lower extremities. With the rising incidences of these problems, various digital care solutions have been introduced in the country to help people with diabetes. For instance, there has been a rise in the usage of real-life and -time behavioral and metabolic data for informing patients about the current insulin levels and helping them make treatment decisions. Other than this, the German federal disease control and prevention research institute, Robert Koch Institute (RKI), has been developing a public health surveillance system. It focuses on the collection of comparable, long-term data, and ensuring the establishment of efficient surveillance structures for monitoring relevant indicators of diabetes.

Moreover, several initiatives are being undertaken in the country to spread awareness about the rising prevalence of diabetes, which mostly occurs in children and adolescents. In June 2019, the 2nd World Conference on Diabetes and Endocrinology was organized in Berlin, which included various research presentations provided by global leaders in diabetes and endocrinology. Besides this, in 2019, a country-wide campaign, called ‘Sche1sstyp’, was initiated by the Germany-based research center, Helmholtz Zentrum München. The campaign addresses the prevention and early detection of type 1 diabetes.

What we have achieved in this report:

Comprehensive situation analysis of the Germany diabetes epidemiology and its dynamics:

Focus of the Analysis:

• Historical, current and future prevalence of diabetes in Germany
• Historical, current and future prevalence of type-1 and type-2 diabetes in Germany
• Historical, current and future prevalence of diabetes in the urban and rural regions in Germany
• Historical, current and future prevalence of diabetes among males and females in Germany
• Historical, current and future prevalence of diabetes among various age groups in Germany
• Historical, current and future diagnosis rates for diabetes in Germany
• Historical, current and future drug treatment rates for diabetes in Germany
   

Comprehensive situation analysis of the Germany Oral Antidiabetics market and its dynamics:

Focus of the Analysis:

• Performance of the Oral Antidiabetics market in Germany
• Performance of key classes
• Performance of key players
• Market outlook
   

Comprehensive situation analysis of the Germany Insulin market and its dynamics:

Focus of the Analysis:

• Performance of the Insulin market in Germany
• Performance of key classes
• Performance of key players
• Market outlook